Daré Bioscience to Participate in Xpectives.Health SUMMIT Innovations in Women’s Health Business Conference
April 17 2023 - 8:00AM
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health
innovation, today announced that Sabrina Martucci Johnson, the
company’s President and CEO, will participate in a panel discussion
at the Innovations in Women’s Health Business Conference, hosted by
Xpectives.Health, on April 20, 2023 at Westin Copley Place, Boston,
MA.
Panel: |
|
What’s Hot and
What’s Next in Women’s Health…Innovators in Women’s Health |
|
|
|
Date: |
|
April 20, 2023 |
|
|
|
Time: |
|
4:00-4:45 p.m. Eastern Time |
|
|
|
Panelists: |
|
Amanda Gorman, PNP, Founder, Nest Collaborative Telelactation
ConsultationSabrina Martucci Johnson, President and CEO, Daré
BioscienceChristine Henningsgaard, CEO, Quilted Health Emily
Sylvester, MS, RD, LDN, IBCLC, Founder and CEO, Mother of Fact |
|
|
|
Details: |
|
Women’s Health inventors, founders and innovators will share
innovative products and services available currently, and what is
in the Women’s Health product pipeline that will positively impact
health care for women. |
|
|
|
For additional information on the conference,
please visit https://xpectives.health/womens-health/
About Daré Bioscience
Daré Bioscience is a biopharmaceutical company
committed to advancing innovative products for women’s health. The
company’s mission is to identify, develop and bring to market a
diverse portfolio of differentiated therapies that prioritize
women's health and well-being, expand treatment options, and
improve outcomes, primarily in the areas of contraception, vaginal
health, reproductive health, menopause, sexual health and
fertility.
Daré’s first FDA-approved product,
XACIATO™ (clindamycin phosphate) vaginal gel, 2% is a
lincosamide antibacterial indicated for the treatment of bacterial
vaginosis in female patients 12 years of age and older, which is
under a global license agreement with Organon. XACIATO is a clear,
colorless, viscous gel, to be administered once intravaginally as a
single dose. Daré’s portfolio also includes potential
first-in-category candidates in clinical development: Ovaprene®, a
novel, hormone-free monthly intravaginal contraceptive
whose U.S. commercial rights are under a license
agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream
formulation of sildenafil to treat female sexual arousal disorder
utilizing the active ingredient in Viagra®; and DARE-HRT1, a
combination bio-identical estradiol and progesterone intravaginal
ring for menopausal hormone therapy. To learn more about XACIATO,
Daré’s full portfolio of women’s health product candidates, and
Daré’s mission to deliver differentiated therapies for women,
please visit www.darebioscience.com.
Daré may announce material information about its
finances, product and product candidates, clinical trials and other
matters using the Investors section of its website
(http://ir.darebioscience.com), SEC filings, press releases, public
conference calls and webcasts. Daré will use these channels to
distribute material information about the company, and may also use
social media to communicate important information about the
company, its finances, product and product candidates, clinical
trials and other matters. The information Daré posts on its
investor relations website or through social media channels may be
deemed to be material information. Daré encourages investors, the
media, and others interested in the company to review the
information Daré posts in the Investors section of its website and
to follow these Twitter accounts: @SabrinaDareCEO and
@DareBioscience. Any updates to the list of social media channels
the company may use to communicate information will be posted in
the Investors section of Daré’s website.
Contacts:
Investors on behalf of Daré Bioscience, Inc.:Lee Roth Burns
McClellanlroth@burnsmc.com212.213.0006
OR
Media on behalf of Daré Bioscience, Inc.:Jake RobisonEvoke
Canale jake.robison@evokegroup.com 619.849.5383
Source: Daré Bioscience, Inc.
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Jul 2023 to Jul 2024